Emcure Launches Poviztra: A New Semaglutide Option for Weight Management in India

Emcure Launches Poviztra: A New Semaglutide Option for Weight Management in India

By, Admin 23 December 2025

India’s obesity burden is rising fast. Emcure Pharmaceuticals is stepping in with a new treatment option. The company has announced the commercial launch of Poviztra (semaglutide injection) across India, expanding access to evidence-backed weight management therapy.

What Is Poviztra?

Poviztra is a once-weekly semaglutide injection designed for chronic weight management.

Key highlights:

  • Second brand of Novo Nordisk’s semaglutide for weight management
  • Exclusively distributed and commercialised by Emcure in India
  • Delivered via a prefilled, easy-to-use pen device

Available Strengths and Pricing

Poviztra is available in five dosing strengths:

  • 0.25 mg
  • 0.5 mg
  • 1.0 mg
  • 1.7 mg
  • 2.4 mg (maintenance dose)

Pricing starts at ₹8,790 per month, covering four weekly doses.

The pen device allows precise dosing with minimal administration complexity, improving patient adherence.

Clinical Evidence Behind Semaglutide

Semaglutide is not new to the global market.

Its credentials include:

  • Backed by the STEP and SELECT clinical trial programmes
  • Nearly 10 years of global market presence
  • Over 38 million patient-years of exposure
  • Strong safety and efficacy profile supported by real-world data

In clinical trials, many patients achieved over 20% weight loss.

Approved Indications

Poviztra is indicated for adults as an adjunct to diet and exercise in:

  • Obesity (BMI ≥30 kg/m²)
  • Overweight (BMI ≥27 kg/m²) with at least one comorbidity, such as:
    • Type 2 diabetes
    • Hypertension
    • Dyslipidaemia

It is also approved to:

  • Reduce the risk of major adverse cardiovascular events
  • Applicable for patients with cardiovascular disease and obesity or overweight

Why This Launch Matters?

India faces a serious obesity challenge:

  • ~254 million people with generalised obesity
  • ~351 million with abdominal obesity

Obesity is linked to 230+ health complications, including cardiovascular disease, fatty liver, osteoarthritis, PCOS, kidney disease, and Alzheimer’s.

According to Emcure’s leadership, Poviztra aims to close the gap between clinical innovation and real-world access.

Emcure’s Strategic Play

With Poviztra, Emcure is leveraging:

  • Its pan-India distribution network
  • Strong experience in commercialising complex therapies
  • A growing focus on chronic and lifestyle-related diseases

The launch reinforces Emcure’s push toward patient-centric, science-led therapies in high-burden disease areas.

The Bigger Picture

Weight management is shifting from lifestyle advice to clinically validated pharmacotherapy. With Poviztra, Emcure positions itself early in India’s fast-evolving obesity treatment market. For patients, it means more choice, broader access, and evidence-backed care.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!